January 11, 2017 - By Clifton Ray · 0 Comments
The stock of Edwards Lifesciences Corporation (NYSE:EW) registered an increase of 26.62% in short interest. EW’s total short interest was 2.41 million shares in January as published by FINRA. Its up 26.62% from 1.91 million shares, reported previously. With 2.97M shares average volume, it will take short sellers 1 days to cover their EW’s short positions. The short interest to Edwards Lifesciences Corporation’s float is 1.14%. About 1.28M shares traded hands. Edwards Lifesciences Corp (NYSE:EW) has declined 2.33% since June 7, 2016 and is downtrending. It has underperformed by 9.75% the S&P500.
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The company has a market cap of $21.34 billion. The Firm makes heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It has a 38.99 P/E ratio. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.
Out of 25 analysts covering Edwards Lifesciences Corp (NYSE:EW), 20 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 80% are positive. Edwards Lifesciences Corp has been the topic of 54 analyst reports since July 30, 2015 according to StockzIntelligence Inc. The company was maintained on Wednesday, April 27 by Citigroup. The stock of Edwards Lifesciences Corp (NYSE:EW) earned “Neutral” rating by SunTrust on Friday, January 8. The company was downgraded on Tuesday, September 22 by Zacks. The rating was upgraded by Wells Fargo to “Priority List” on Monday, October 19. Guggenheim upgraded the stock to “Buy” rating in Tuesday, January 3 report. Cowen & Co maintained it with “Outperform” rating and $120 target price in Wednesday, April 27 report. The company was maintained on Monday, April 11 by JP Morgan. The firm has “Outperform” rating given on Monday, April 4 by BMO Capital Markets. RBC Capital Markets maintained Edwards Lifesciences Corp (NYSE:EW) rating on Wednesday, October 26. RBC Capital Markets has “Outperform” rating and $123 price target. The rating was initiated by Nomura with “Buy” on Thursday, March 17.
Edwards Lifesciences Corporation, incorporated on September 10, 1999, is focused on technologies that treat structural heart disease and critically ill patients. The Firm makes heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. The Firm conducts activities around the world and is managed in various geographical regions, including the United States, Europe, Japan, and Rest of World. All regions sell products that are used to treat advanced cardiovascular disease. The Company’s products and technologies it offers to treat advanced cardiovascular disease are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.
More notable recent Edwards Lifesciences Corp (NYSE:EW) news were published by: Fool.com which released: “Why Edwards Lifesciences Corp Got Crushed by Investors Today” on October 26, 2016, also Marketwatch.com with their article: “Edwards Lifesciences hikes outlook on strong sales” published on July 26, 2016, Fool.com published: “Why Edwards Lifesciences Shares Are Surging 17% Today” on April 04, 2016. More interesting news about Edwards Lifesciences Corp (NYSE:EW) were released by: Wsj.com and their article: “Edwards Lifesciences Raises 2016 View as Earnings, Revenue Top Estimates” published on April 26, 2016 as well as Nasdaq.com‘s news article titled: “Agree To Buy Edwards Lifesciences Corp At $70, Earn 5.9% Using Options” with publication date: December 20, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Clifton Ray